Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
CAR T-cell therapy is a promising new treatment for some of the most challenging childhood leukemia and lymphoma cases. The immunotherapy treatment uses the body's T cells, a type of immune system cell, to eliminate cancer cells.
Researchers and physicians at Dana-Farber/Boston Children's Cancer and Blood Disorders Center are undertaking leading-edge research to advance CAR T-cell therapy in childhood acute lymphoblastic leukemia treatment and childhood non-Hodgkin lymphoma treatment.
KYMRIAH® is a form of CAR T-cell therapy, and is approved by the FDA as the standard of care for some forms of childhood ALL including relapsed ALL.
Find out more about how we treat childhood ALL.
We use KYMRIAH to treat children and young adults with relapsed or refractory large B-cell lymphomas, including:
Read more about how we treat childhood non-Hodgkin lymphoma.
This video describes the eight steps of the CAR T-cell therapy process.
CAR T-cell therapy uses genetically engineered cells to attack cancer cells. The process includes:
New Patient Appointments